Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab vs Thymoglobuline in RIC Allogeneic Transplant
NCT00354120Phase 3Completed
- Sponsor
- GITMO
- Start
- Mar 2005
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of alemtuzumab in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 11 more, sponsored by GITMO. Primary endpoint: Overall Survival at 3 years. Started Mar 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)Chronic Myeloid Leukemia (CML)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT00354120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354120.